FDA awards grant for cancer drug study

The US FDA has awarded a $1.6m grant under its orphan drugs programme to a Alabama-based biotech company Egen to help the company with clinical trials of a potential new therapy for ovarian cancer

The US Food and Drug Administration (FDA) has awarded a $1.6m grant under its orphan drugs programme to a small, Alabama-based biotech company called Egen to help the company with clinical trials of a potential new therapy for ovarian cancer.

The four-year grant is intended to assist in the phase II clinical development of the privately held company's lead product, Egen-001, which is being developed for the treatment of advanced recurrent ovarian cancer.

The drug is an interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 enhances the body's immune system against cancer and inhibits tumour blood supply, according to Egen.

The product has completed two phase I trials: one as monotherapy in platinum-resistant ovarian cancer patients, and the other in combination with carboplatin/docetaxel chemotherapy in platinum-sensitive ovarian cancer patients.

The FDA granted orphan drug status to Egen-001 in 2005. The status, which is reserved for drugs intended to treat diseases that affect fewer than 200,000 Americans, carries a number of benefits, including seven years of US marketing exclusivity, tax breaks and eligibility for help with clinical trial costs.

This is Egen's second grant for the drug from the FDA. The first, totaling $1m, was awarded in 2005.

3rd February 2011

PME Digital Edition

Featured jobs

Digital Account Director: Salary TBC

Senior Account Manager, Medical Communications, London: Excellent package

EU Head of Business Development and Client Service: Exceptional packge and bonus

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Creative/ Medical Writer: Circa £35, 000 With Benefits

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Account Director, Healthcare Marketing Agency: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Health Consultant - Brand Comms: Competitive Salary

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Home-based Medical Writer – Medical Education: Salary TBC

Scientific Director – Medical Communications: Salary TBC

Freelance AM/ AD Healthcare Advertising: £350-400 depending on experience

Home based, Senior Medical Writer, Medical Communications: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home-based Senior Medical Writer – Med Ed: Salary TBC

Senior Digital Health Specialist – Global Agency: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Freelance Senior Account Manager / Account Director - Healthcare...: £350-400 depending on experience

“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”: The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029: Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019: International Women's Day has been celebrated since its inception in 1911. But how far have we come?...